Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Josiah E HardestyDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Jeffrey B WarnerDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Daniel W WilkeyThe Proteomics Core, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0001-7491-7696
Brett S PhinneyProteomics Core Facility, University of California Davis, Davis, CA 95616, USA.ORCID 0000-0003-3870-3302
Michelle R SalemiProteomics Core Facility, University of California Davis, Davis, CA 95616, USA.
Michael L MerchantDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Craig J McClainDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-7219-8939
Dennis R WarnerDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Irina A KirpichAlcohol Research Center, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Funding
Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN · 2016 to 2026
$17.9M
Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
Role of Soluble Epoxide Hydrolase in Alcohol-Associated Liver DiseaseR01AA028905 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Irina A. Kirpich · 2022 to 2026
$2.1M
Mechanisms for alcohol induced gut barrier dysfunction in ALDR01AA023681 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2014 to 2018
$1.6M
Restoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AHR00AA030627 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Josiah E Hardesty · 2024 to 2026
$732k
Phinney - Orbitrap Fusion ETDS10OD021801 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PHINNEY, BRETT S · 2016 to 2016
$600k
Pilot Trial UO1 DUR-928U01AA026934 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2018 to 2022
$356k
RvD1-FPR2 signaling ameliorates alcoholic liver diseaseF32AA027950 · NIAAA · UNIVERSITY OF LOUISVILLE · PI HARDESTY, JOSIAH E · 2020 to 2022
$164k
sEH Inhibition in Alcoholic Liver Disease: A Novel Therapeutic StrategyF31AA028423 · NIAAA · UNIVERSITY OF LOUISVILLE · PI WARNER, JEFFREY B · 2020 to 2022
Alcohol-associated liver disease (ALD) is a prevalent medical problem with limited effective treatment strategies. Although many biological processes contributing to ALD have been elucidated, a complete understanding of the underlying mechanisms is still lacking. The current study employed a proteomic approach to identify hepatic changes resulting from ethanol (EtOH) consumption and the genetic ablation of the formyl peptide receptor 2 (FPR2), a G-protein coupled receptor known to regulate multiple signaling pathways and biological processes, in a mouse model of ALD. Since previous research from our team demonstrated a notable reduction in hepatic FPR2 protein levels in patients with alcohol-associated hepatitis (AH), the proteomic changes in the livers of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Hepatic Proteomic Changes Associated with Liver Injury Caused by Alcohol Consumption in · full record | Socratic